MergerMay 14, 2026, 07:21 AM
Galera to Merge with Obsidian; $350M PIPE Financing
AI Summary
Galera Therapeutics, Inc. announced a definitive merger agreement with Obsidian Therapeutics, Inc., which will result in a combined company focused on engineered TIL cell therapies. Concurrently, Galera entered into a securities purchase agreement for a Private Investment in Public Equity (PIPE) financing of approximately $350.0 million. The company also reported a net loss of $1.61 million for Q1 2026 and holds $5.50 million in cash and cash equivalents, with management concluding substantial doubt about its ability to continue as a going concern without the merger.
Key Highlights
- Entered into a merger agreement with Obsidian Therapeutics, Inc.
- Secured approximately $350.0 million in PIPE financing concurrent with the merger.
- Sold avasopasem and rucosopasem assets to Biossil for $3.5 million upfront, with potential for $105.0 million in contingent value rights.
- Reported a net loss of $1,606 thousand for the three months ended March 31, 2026.
- Cash and cash equivalents totaled $5,500 thousand as of March 31, 2026.
- Accumulated deficit reached $308.9 million as of March 31, 2026.
- Research and development expenses decreased to $15 thousand in Q1 2026 from $93 thousand in Q1 2025.
- General and administrative expenses decreased to $1,640 thousand in Q1 2026 from $1,870 thousand in Q1 2025.